Sign in to view content

Intravitreal Aflibercept 8 mg in Patients With Polypoidal Choroidal Vasculopathy Phase 3 PULSAR Trial Subgroup Analysis

David T.W. Wong, MD, FRCS(C), FASRS

Video
Published 2023

Related

12-Month Results of EYP-1901 Vorolanib in a Bioerodible Durasert Insert for nAMD: The DAVIO Trial
Rishi P. Singh, MD
Updates from the Field
2022
Key Pearls of Conjunctival and Tenon’s Capsule Handling During the Implant Insertion Procedure for the Port Delivery System With Ranibizumab (PDS)
Veeral S. Sheth, MD, MBA, FASRS, FACS
Annual Meeting Talks
2021
An Assessment of the Impact of Disease Activity Criteria on Dosing Interval Assignment in Clinical Trial Patients With nAMD
Marco A. Zarbin, MD, PhD
Annual Meeting Talks
2023

Category: AMD-Neovascular

See more